[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adverse-pregnancy-outcome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adverse-pregnancy-outcome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100516450","phase-2-using-placental-pathology-to-prevent-recurrent-adverse-pregnancy-outcomes-a-pilot-project-100516450",false,"NCT06004674","Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project","Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project (UPPPP Trial)","Eligibility Criteria:\n\nInclusion (must meet all three criteria):\n\n1. Subjects with a prior adverse outcome in a prior pregnancy. Adverse outcome is defined as prior singleton preterm birth ( \\\u003C 37 weeks), SGA infant (defined as birthweight \\\u003C 10th percentile), preeclampsia with severe features, or stillbirth (fetal demise after 20 weeks gestation), as certified by an obstetrician\n2. Patients with maternal vascular malperfusion on pathology from pregnancy with prior adverse pregnancy outcome, as certified by a perinatal placental pathologist\n3. Current singleton pregnancy at \\\u003C16 6\u002F7 weeks gestational age.\n\nExclusion Criteria:\n\n1. Anticoagulation planned for current pregnancy (including warfarin, enoxaparin, heparin)\n2. Known major fetal anomaly\n3. Contraindication to enoxaparin: Specifically active major bleeding, known thrombocytopenia (platelets \\\u003C100), hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol\n4. Chronic kidney disease with eGFR\\\u003C 60\n5. Known chronic liver disease with baseline AST\u002FALT \\> 3 x upper limit of normal\n6. Subjects with mechanical prosthetic heart valves","ALL","18 Years","60 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide treatment in the subsequent pregnancy and reduce risk of recurrent adverse pregnancy events.\n\nThe main questions it aims to answer are:\n\n* Whether enoxaparin prevents recurrent adverse pregnancy outcomes among patients with a prior adverse pregnancy outcome that occurred in the setting of maternal vascular malperfusion (MVM).\n* If enoxaparin reduces the occurrence or severity of MVM among patients with a prior adverse pregnancy outcome that occurred in the setting of MVM.",[27],"Adverse Pregnancy Outcome",[29,30,31,32,33],"miscarriage","preeclampsia","preterm delivery","stillbirth","Low birth weight","RECRUITING","2025-07-29",{"date":37,"type":38},"2025-07-31","ACTUAL",{"date":40,"type":38},"2023-12-26",{"date":42,"type":21},"2026-03",{"name":44,"class":45},"Endeavor Health","OTHER"]